Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pharmacokinetics of methyldopa in healthy man.

Literature DB >> 923625

Pharmacokinetics of methyldopa in healthy man.

O Stenbaek, E Myhre, H E Rugstad, E Arnold, T Hansen.

Abstract

Entities: Chemical Species

Mesh：

Substances：
Methyldopa

Year: 1977 PMID： 923625 DOI： 10.1007/bf00645132

Source DB: PubMed Journal: Eur J Clin Pharmacol ISSN： 0031-6970 Impact factor: 2.953

× No keyword cloud information.

12 in total

1. THE METABOLISM OF METHYLDOPA IN HYPERTENSIVE HUMAN SUBJECTS.

Authors: R P BUHS; J L BECK; O C SPETH; J L SMITH; N R TRENNER; P J CANNON; J H LARAGH
Journal: J Pharmacol Exp Ther Date: 1964-02 Impact factor: 4.030

2. STUDIES ON THE METABOLISM AND MECHANISM OF ACTION OF METHYLDOPA.

Authors: A SJOERDSMA; A VENDSALU; K ENGELMAN
Journal: Circulation Date: 1963-10 Impact factor: 29.690

3. Plasma turnover of methyldopa in advanced renal failure.

Authors: E Myhre; E K Brodwall; O Stenbaek; T Hansen
Journal: Acta Med Scand Date: 1972-04

4. Hypotensive effect of methyldopa in renal failure associated with hypertension.

Authors: O Stenbaek; E Myhre; E K Brodwall; T Hansen
Journal: Acta Med Scand Date: 1972-04

5. Conjugation of methyldopa in renal failure.

Authors: E Myhre; O Stenbaek; E K Brodwall; T Hansen
Journal: Scand J Clin Lab Invest Date: 1972-04 Impact factor: 1.713

6. The renal excretion of methyldopa.

Authors: E Myhre; E K Brodwall; O Stenbaek; T Hansen
Journal: Scand J Clin Lab Invest Date: 1972-04 Impact factor: 1.713

7. [Pharmacokinetics of alpha-methyldopa in kidney failure].

Authors: K Schrader; H Brass; D Renner
Journal: Klin Wochenschr Date: 1971-12-15

8. Plasma concentration of alpha-methyldopa and sulphate conjugate after oral administration of methyldopa and intravenous administration of methyldopa and methyldopa hydrochloride ethyl ester.

Authors: J A Saavedra; J L Reid; W Jordan; M D Rawlins; C T Dollery
Journal: Eur J Clin Pharmacol Date: 1975-08-14 Impact factor: 2.953

9. Combined clinical and metabolic study of the effects of alpha-methyldopa on hypertensive patients.

Authors: L F Prescott; R P Buhs; J O Beattie; O C Speth; N R Trenner; L Lasagna
Journal: Circulation Date: 1966-08 Impact factor: 29.690

10. The metabolism of 14 C-labelled -methyldopa in normal and hypertensive human subjects.

Authors: W Y Au; L G Dring; D G Grahame-Smith; P Isaac; R T Williams
Journal: Biochem J Date: 1972-08 Impact factor: 3.857

7 in total

1. Use of the peptide carrier system to improve the intestinal absorption of L-alpha-methyldopa: carrier kinetics, intestinal permeabilities, and in vitro hydrolysis of dipeptidyl derivatives of L-alpha-methyldopa.

Authors: M Hu; P Subramanian; H I Mosberg; G L Amidon
Journal: Pharm Res Date: 1989-01 Impact factor: 4.200

2. alpha-Methyldopa, alpha-methyldopamine an alpha-methylnoradrenaline: substrates for the thermolabile form of human platelet phenol sulphotransferase.

Authors: G Mwaluko; R Weinshilboum
Journal: Br J Clin Pharmacol Date: 1982-08 Impact factor: 4.335